

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonapplications under 37C.F.R. §1.53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

Attorney Docket No.

PC9400C

First Inventor

Stuart GREEN

Title

TRIAZOLE DERIVATIVES USEFUL IN  
THERAPY

Express Mail Label No.

EV 291841785 US

ADDRESS TO:

Mail Stop Patent Applications  
Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

1. ☒ **Fee Transmittal Form (e.g., PTO/SB/17)**  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status  
See 37 CFR 1.27
3. ☒ **Specification** [Total Pages 28]  
(preferred arrangement set forth below)
- Descriptive title of the invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the invention
  - Brief Summary of the invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) [Total sheets       ]
5. ☒ **Oath or Declaration** [Total pages 3]
- a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 18 completed)
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 CFR  
1.63(d)(2) and 1.33(b).
6. ☒ **Application Data Sheet. See 37 CFR 1.76**

7. ☐ CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
- a. ☐ Computer Readable Copy (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies)
    - ii. ☐ Paper
  - c. ☐ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122  
(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other:

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.

☐ Continuation ☒ **Divisional** ☐ Continuation-in-part (CIP) of prior application No: 10/339,087


Prior application information: Examiner Patricia L. Morris Group/Art Unit: 1625

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

**19. CORRESPONDENCE ADDRESS**

☒ Customer Number 28940 or ☐ Correspondence address below

Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	

NAME (Print/type)	Elsa Djuardi	Registration No. (Attorney/Agent)	45,963
Signature		Date	03-26-2004

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment \$ 770.00

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number  
Deposit  
Account  
Name

500329

Agouron Pharmaceuticals, Inc.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	770
1002	340	2002	170	Design filing fee	
1003	530	2203	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	filing fee	

Subtotal (1)s \$ 770

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	3 - 20** = 0	x 0	= 0
Independent Claims	3 - 3 = 0	x 18	= 0
Multiple Dependent			= 0

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue independent claims over original patent

(\$) 0

\*\*or number previously paid, if greater; For Reissues, see above

## Complete if Known

Application Number	To be Assigned
Filing Date	To be Assigned
First Named Inventor	Stuart GREEN
Examiner Name	To be Assigned
Art Unit	To be Assigned
Attorney Docket No.	PC9400C

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1051	130	2051 65	Surcharge - late fee or oath
		1052	50	2052 25	Surcharge-late filing fee or cover sheet
		1053	130	1053 130	Non-English specification
		1812	2,520	1812 2,520	For filing a request for Ex Parte reexamination
		1804	920*	1804 920*	Requesting publication of SIR prior to Examiner action
		1805	1,840*	1805 1,840*	Requesting publication of SIR after Examiner action
		1251	110	2251 55	Extension for reply within first month
		1252	420	2252 210	Extension for reply within second month
		1253	950	2253 475	Extension for reply within third month
		1254	1,480	2254 740	Extension for reply within fourth month
		1255	2,010	2255 1,005	Extension for reply within fifth month
		1401	330	2401 165	Notice of Appeal
		1402	330	2402 165	Filing a brief in support of an appeal
		1403	290	2403 145	Request for oral hearing
		1451	1,510	1451 1,510	Petition to institute a public use proceeding
		1452	110	2452 55	Petition to revive unavoidable
		1453	1,330	2453 665	Petition to revive - unintentional
		1501	1,330	2501 665	Utility issue fee (or reissue)
		1502	480	2502 240	Design issue fee
		1503	640	2503 320	Plant issue fee
		1460	130	1460 130	Petitions to the Commissioner
		1807	50	1807 50	Processing fee under 37 CFR 1.17(q)
		1806	180	1806 180	Submission of Information Disclosure Stmt
		8021	40	8021 40	Recording each patent assignment per property (times number of properties)
		1809	770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))
		1810	770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))
		1801	770	2801 385	Request for Continued Examination (RCE)
		1802	900	1802 900	Request for expedited examination of a design application


Other Fee (specify)

\*Reduced by Basic Filing Fee Paid

Subtotal (3)

(\$)

## SUBMITTED BY

Name (Printed/Type)	Elsa Ojuardi	Registration No.	45,963	Telephone	858 638-6117
Signature		(Attorney Agent)			


Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.

PC9400C  
Divisional Patent Application

Certificate of Mailing (37 C.F.R. §1.10):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail (**EV 291841785 US**) in an envelope addressed to:  
Mail Stop: Patent Applications  
Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 26th day of March 2004.

s/   
Pamela Hollander

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
Stuart GREEN, et al.

Serial No.:  
To be Assigned, Divisional of 10/339,087

Filed: Herewith

For: **TRIAZOLE DERIVATIVES USEFUL IN  
THERAPY**

Group Art Unit: To be Assigned

Examiner: To be Assigned


Mail Stop: Patent Applications  
Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

- |  |                               |
|--|-------------------------------|
| 1. Return Receipt Postcard                         | 1 postcard;                   |
| 2. Application Data Sheet                          | 1 page;                       |
| 3. Utility Patent Application Coversheet           | 1 page;                       |
| 4. Preliminary Amendment                           | 3 pages;                      |
| 5. Specification                                   | 28 total pages;               |
| ▪ Claims   | 2 pages;                      |
| ▪ Abstract   | 1 page;                       |
| 6. Six pages of IPER Amended Pages                 | 6 pages;                      |
| 7. Transmittal of Information Disclosure Statement | 2 pages;                      |
| 8. Copy of Information Disclosure Statement;       | 4 pages;                      |
| 9. Copy of Recorded Assignment;                    | 3 pages;                      |
| 10. Copy of Power of Attorney form;                | 3 pages;                      |
| 11. Consent of Pfizer, Ltd.                        | 2 pages;                      |
| 12. Copy of Declaration                            | 3 pages; and                  |
| 13. Fee Transmittal                                | Deposit Account (+ duplicate) |

Respectfully submitted,



Elsa Djuardi  
Attorney For Applicants  
Registration No. 45,963

Date: March 26, 2004

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-6117